Pfizer rises nearly 2% after it seeks nod for vaccine authorization in India

Mumbai: Shares of Pfizer rose nearly 2 per cent after the drug maker became the first to seek from the Drugs Controller General of India (DCGI) an emergency use authorisation for its Covid-19 vaccine in the country after its parent company secured such clearance in the UK and Bahrain.

At 9:15 am, Pfizer was up 1.88 per cent at Rs 5,355.15, while benchmark Sensex dropped 0.05 per cent to 45,057.39 points.

A committee of experts is likely to meet this week to consider Pfizer Inc’s application seeking emergency use authorisation for its Covid vaccine in India, which the US drug maker said would only be supplied through government contracts during the pandemic phase.


The parent firm US pharma giant Pfizer is working out elaborate cold storage plans to ensure temperature integrity of its vaccine that requires to be maintained at -70 degree Celsius.